Novo Underwhelms Investors With Soft Wegovy Pill Sales
Novo Nordisk A/S’s popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the hype of an obesity drug whose launch was billed the most successful in history.
This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:
Read full article at Bloomberg Markets
